• Da-Jyun Su, Jyh-Feng Lu, Li-Ju Lin, Jao-Shwann Liang, and Kun-Long Hung.
• Department of Pediatrics, Cathay General Hospital, Taipei, Taiwan.
• Brain Dev. 2018 Sep 1; 40 (8): 724-727.

AbstractSCN2A mutations have been identified in various encephalopathy phenotypes, ranging from benign familial neonatal-infantile seizure (BFNIS) to more severe forms of epileptic encephalopathy such as Ohtahara syndrome or epilepsy of infancy with migrating focal seizure (EIMFS). Thus far, no particularly effective treatment is available for severe epileptic encephalopathy caused by SCN2A mutations in children. We present the case of a boy who developed seizures on the third day of life and received a diagnosis of EIMFS based on his clinical presentations and electroencephalography reports. Antiepileptic drugs, namely oxcarbazepine, phenytoin, valproate, levetiracetam, and clonazepam, as well as adrenocorticotropic hormone therapy failed to reduce the severity of the seizures. Seizure pattern changed to infantile spasm with extensor thrust since 5 months of age. A ketogenic diet consisting of a medium-chain triglyceride recipe was introduced at 8 months of age and the seizures were resolved in the following 10 months. A de novo mutation in SCN2A (c.573G > T; p.W191C) was proven through next-generation sequencing.Copyright © 2018 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

24 keywords...

hide…